Browsing Tag
XCOPRI
3 posts
Biohaven gets $400m near-term cash as SK Biopharmaceuticals takes opakalim rights
SK Biopharmaceuticals will pay Biohaven $400 million in near-term cash and up to $395 million in additional milestones for global rights to opakalim and its Kv7 platform, while pivotal epilepsy data remain pending.
SK Biopharmaceuticals launches phase 3 trial of seizures drug cenobamate in Asia
SK Biopharmaceuticals, a South Korean pharma company, has revealed plans to initiate a phase 3 clinical trial for…
SK Biopharmaceuticals bags XCOPRI FDA approval for partial-onset seizures
XCOPRI FDA approval : SK Biopharmaceuticals said that its US subsidiary SK Life Science has been granted approval from…